Core Insights - Roche's late-stage study FENhance 1 for fenebrutinib in relapsing multiple sclerosis (RMS) met its primary endpoint, showing significant efficacy [1][8] - Fenebrutinib demonstrated a 51% reduction in RMS relapses compared to teriflunomide in FENhance 1, with FENhance 2 showing a 59% reduction [3][8] - The comprehensive data from the phase III studies will be submitted to regulatory authorities, with the potential for fenebrutinib to become a leading oral therapy for both RMS and primary progressive multiple sclerosis (PPMS) [5][8] Study Details - The phase III program includes two trials in RMS (FENhance 1 and 2) and one trial in PPMS (FENtrepid), evaluating fenebrutinib against teriflunomide and Ocrevus respectively [2] - FENhance 1 and FENhance 2 involved 1,497 adult patients and were designed as multicenter, randomized, double-blind studies [3] Safety and Efficacy - Safety findings were comparable to teriflunomide, with similar liver enzyme elevations and one case of Hy's Law in each treatment arm, both resolving after treatment discontinuation [5] - Secondary endpoints showed statistically significant reductions in brain lesions, indicating strong benefits across both relapsing and progressive disease processes [4] Portfolio Impact - Successful development of fenebrutinib will enhance Roche's neuroscience portfolio, which includes Ocrevus, a key growth driver for the company [6] - Roche is actively developing over a dozen therapies for various neurological conditions, including multiple sclerosis and Alzheimer's disease [6] Competitive Landscape - Roche's Ocrevus and Vabysmo are performing strongly, helping to offset revenues from legacy drugs [7] - Positive data from fenebrutinib and other candidates like giredestrant may increase the likelihood of regulatory approval, serving as a catalyst for Roche's stock [9]

The drugmaker said the results provide convincing evidence that fenebrutinib can become the first high-efficacy oral treatment for relapsing and primary progressive multiple sclerosis. https://t.co/oo2aUPh8rJ ...

Core Insights - Roche announced that the pivotal Phase III study (FENhance 1) of fenebrutinib in relapsing multiple sclerosis (RMS) met its primary endpoint, showing a 51% reduction in annualized relapse rate (ARR) compared to teriflunomide over at least 96 weeks of treatment [1][8] - Secondary endpoints in both RMS studies indicated statistically significant reductions in brain lesions, with all progression endpoints showing favorable trends for fenebrutinib [1][8] Study Details - FENhance 1 and 2 are Phase III multicenter, randomized, double-blind studies evaluating fenebrutinib against teriflunomide in 1,497 adult patients with RMS, with participants randomized 1:1 for treatment over at least 96 weeks [7][8] - The primary endpoint is ARR, while secondary endpoints include MRI lesion counts and measures of disability progression [9] Safety Profile - Liver transaminase elevations in both RMS studies were comparable to teriflunomide, with one Hy's Law case in each treatment arm, both of which were asymptomatic and resolved after discontinuation [4] - In the FENhance studies, one fatal case was reported in the teriflunomide arm and eight in the fenebrutinib arms, with further analyses ongoing to understand these findings [5] Mechanism of Action - Fenebrutinib targets B cells and microglia to control acute inflammation and address chronic damage, designed to be a high-potency, reversible BTK inhibitor that can penetrate the central nervous system [6][11][12] Future Plans - Full data from the FENhance studies will be presented at the American Academy of Neurology Annual Meeting 2026 and submitted to regulatory authorities alongside data from the FENtrepid study [2]

Company Overview - TG Therapeutics was founded in 2012, focusing on B-cell-mediated diseases, including autoimmune diseases, neuroinflammatory conditions, and cancer [3] - The company is primarily focused on multiple sclerosis (MS) and has one approved drug, BRIUMVI, which is approaching blockbuster status [3] Product Information - BRIUMVI is an anti-CD20 monoclonal antibody that was approved in late December 2022 and launched in January 2023 [4] - The drug is not only available in the U.S. but has also been launched globally [4] Clinical Development - TG Therapeutics has two pivotal trials ongoing to expand the utilization and total addressable market for BRIUMVI [3] - The company has three additional programs under development [3]